Skip to main content

Wanda Phipatanakul

NIH Rank #1096
  • Program Leader
  • Top 10% Funded
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 2099802Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$3.5M
Full award amounts, FY2026
Award Records
3
Records listing this PI
Award-Linked Rank
#1,096
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Wanda Phipatanakul. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Wanda Phipatanakul as a PI. Multi-PI records show the full award amount for context.

  • 5U01AI179563-03U01
    Controlling and Preventing Asthma Progression and Severity in Kids with Omalizumab Extension (PARK-EXT)
    $2.3M
    award amount
  • 5U01AI160087-06U01
    Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
    $759K
    award amount
  • 5U01AI152033-07U01
    Genetic and microbial modifiers of Atopic Dermatitis (AD): Mechanisms of increased AD severity in patients with the R576 polymorphism in IL-4Ra and impact of S aureus skin decolonization on AD
    $525.8K
    award amount

Award organization

Organizations that administered FY2026 awards listing Wanda Phipatanakul as a PI.

FY2026 award administered by Boston Children's Hospital (MA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Boston Children's Hospital
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #2244
  6. 2024
    Entered Top 25% Nationally
    Ranked #2244
  7. 2025
    $5M Cumulative Funding
  8. 2025
    Program/Center Grant Leader
  9. 2026
    $10M Cumulative Funding
  10. 2026
    Entered Top 10% Nationally
    Ranked #1096

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Wanda Phipatanakul.